Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06197308 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
A Early Phase 1 study of Primary Sclerosing Cholangitis, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06197308 is a Early Phase 1 study of Primary Sclerosing Cholangitis that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 28 participants, below the 552-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06197308, a Early Phase 1 study of Primary Sclerosing Cholangitis, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC). This trial will inform development of future trials in treatment of PSC.
Conditions Studied
Interventions
- DRUG oral vancomycin and oral amoxicillin
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2027-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06197308
The ClinicalTrials.gov registry entry for NCT06197308 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 552-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (95% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 1 intervention - of which oral vancomycin and oral amoxicillin is the first listed.
NCT06197308 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06197308 about?
NCT06197308 is a clinical study titled "Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC". This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC). This trial will inform development of future trials in treatment of PSC.
What is the current status of trial NCT06197308?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2024-03-01. Estimated completion is 2027-09-01.
What conditions does trial NCT06197308 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.
What interventions are being tested in trial NCT06197308?
The interventions under investigation include: oral vancomycin and oral amoxicillin (DRUG).
Who is sponsoring clinical trial NCT06197308?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06197308 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
RECRUITING · Early Phase 1
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
RECRUITING
-
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
RECRUITING
-
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
RECRUITING
-
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.